Amoeba SA Total Liabilities

Latest as of December 2025: €15.49 Million EUR ≈ $18.11 Million USD

Amoeba SA total liabilities. Based on the latest financial reports, Amoeba SA (ALMIB) has total liabilities worth €15.49 Million EUR (≈ $18.11 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Amoeba SA (ALMIB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Amoeba SA (2011–2025)

Total liabilities of Amoeba SA from 2011 to 2025. This chart illustrates how Amoeba SA's total liabilities have evolved over time, based on quarterly financial data.

Amoeba SA Competitors by Total Liabilities

The table below lists competitors of Amoeba SA ranked by their total liabilities.

Company Country Total Liabilities
Eclipse Metals Ltd
AU:EPM
Australia AU$120.79K
Aspermont Ltd
AU:ASP
Australia AU$12.17 Million
LS telcom AG
XETRA:LSX
Germany €23.97 Million
Minho M Bhd
KLSE:5576
Malaysia RM66.84 Million
DarioHealth Corp
NASDAQ:DRIO
USA $41.50 Million
Panorama Sentrawisata Tbk
JK:PANR
Indonesia Rp724.87 Billion
Eagon Holdings Co.Ltd
KQ:039020
Korea ₩375.64 Billion

Liability Composition Analysis (2011–2025)

This chart breaks down Amoeba SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Amoeba SA asset portfolio.

Liquidity & Leverage Metrics

Amoeba SA Total Liabilities Ratios Explained

Amoeba SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.98 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.89 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.53 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Amoeba SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Amoeba SA (2011–2025)

The table below shows the annual total liabilities of Amoeba SA from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 €15.49 Million
≈ $18.11 Million
-3.54%
2024-12-31 €16.06 Million
≈ $18.78 Million
+56.99%
2023-12-31 €10.23 Million
≈ $11.96 Million
+141.99%
2022-12-31 €4.23 Million
≈ $4.94 Million
-70.44%
2021-12-31 €14.30 Million
≈ $16.72 Million
+29.28%
2020-12-31 €11.06 Million
≈ $12.93 Million
+15.09%
2019-12-31 €9.61 Million
≈ $11.24 Million
+112841.62%
2018-12-31 €8.51K
≈ $9.95K
-6.05%
2017-12-31 €9.06K
≈ $10.59K
+93.31%
2016-12-31 €4.69K
≈ $5.48K
+32.52%
2015-12-31 €3.54K
≈ $4.13K
-99.87%
2014-12-31 €2.75 Million
≈ $3.22 Million
+52.76%
2013-12-31 €1.80 Million
≈ $2.11 Million
+133.74%
2012-12-31 €770.75K
≈ $901.09K
+16.57%
2011-12-31 €661.17K
≈ $772.98K
--

About Amoeba SA

PA:ALMIB France Agricultural Inputs
Market Cap
$23.28 Million
€19.91 Million EUR
Market Cap Rank
#24435 Global
#391 in France
Share Price
€0.26
Change (1 day)
-2.29%
52-Week Range
€0.26 - €1.11
All Time High
€38.22
About

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopath… Read more